Shijiazhuang Pharmaceutical To Focus On Biopharmaceuticals
This article was originally published in PharmAsia News
Executive Summary
Shijiazhuang Pharmaceutical Group and Unigene Laboratories have started operating their joint venture firm Unigene Biotechnology. Using Unigene Laboratories technology, the new company will produce and sell recombinant calcitonin products. It will also integrate Shijiazhuang's liposome technology and nanobiotechnology to fully develop its core competitiveness. The two partners will invest in biopharmaceutical manufacturing facilities compliant with the current U.S. GMP guidelines, as well as set up a biopharmaceutical laboratory. Shijiazhuang plans to invest 3.54 billion yuan ($516 million) on biopharmaceutical fixed asset to commercialize its pharmaceutical preparations globally. When completed, it expects total revenue to reach 11 billion yuan ($1.6 billion) a year with normal production. (Click here for more - Chinese Language)
|
Shijiazhuang Pharmaceutical Group and Unigene Laboratories have started operating their joint venture firm Unigene Biotechnology. Using Unigene Laboratories technology, the new company will produce and sell recombinant calcitonin products. It will also integrate Shijiazhuang's liposome technology and nanobiotechnology to fully develop its core competitiveness. The two partners will invest in biopharmaceutical manufacturing facilities compliant with the current U.S. GMP guidelines, as well as set up a biopharmaceutical laboratory. Shijiazhuang plans to invest 3.54 billion yuan ($516 million) on biopharmaceutical fixed asset to commercialize its pharmaceutical preparations globally. When completed, it expects total revenue to reach 11 billion yuan ($1.6 billion) a year with normal production. (Click here for more - Chinese Language) "Shijiazhuang Pharmaceutical Group: Breakthrough With Biopharmaceuticals" - ce.cn (6/23/08) |